Developer docs
API playgroundTry for free, no card

Search company profiles

Hercules Capital

Full company profile

uuid00006ru

Namestring
Hercules Capital
Legal namestring
Hercules Capital, Inc.
Websiteurl
htgc.com
Company typeenum
Public
Founded yearint
2003
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Mateo, United States
HQ citystring
San Mateo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture debt financing, senior secured loans, business development company, growth capital lending, non-dilutive financing
Industry3 codes
1Venture Debt with Warrants (Hybrid Debt-Equity)
CodeFSANAIAIPrimaryYes
2Independent Venture Debt Funds / Platforms
CodeFSANAIABPrimaryNo
3Venture Growth / Recurring Revenue Credit Funds
CodeFSANAIAGPrimaryNo
NAICS code2 codes
  • Funds, Trusts, and Other Financial Vehicles525
  • Commercial Banking522110
SIC code1 code
  • Short-Term Business Credit Institutions6153
Product category
Venture Lending / Specialty Finance
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Interest income from senior secured debt investments
TypeSubscription Recurring
Description

Primary revenue stream from interest income on a portfolio of senior secured venture growth loans. Q1 2026 total investment income reached $141.5 million, up 18.4% year-over-year, with $123.4M in total interest income. Portfolio is 98% floating-rate, providing yield upside as base rates rise. Effective portfolio yield was 12.8% in Q1 2026.

stockstory.org
2Equity investment returns and warrants
TypeLicensing Royalties
Description

Equity co-investments alongside debt positions, generating returns through capital gains, dividends, and warrant exercises. Variable component contributes to the supplemental dividend (e.g., $0.07 supplemental added to base $0.40 dividend in Q1 2026).

stocktitan.net
3Net Investment Income (NII)
TypeManaged Services
Description

Record NII of $88.1 million ($0.48 per share) in Q1 2026, representing a 14% year-over-year increase. NII covered the dividend at 120%, demonstrating strong earnings support with $149.1M in spillover income available.

in.investing.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Others, Technology or R&D
Pricing details2 tiers
1Custom venture debt financing — quote-based, not publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is not publicly listed; deal terms are customized per company based on stage, sector dynamics, and capital needs. The company website notes 'We create a custom financing solution for each of our partnerships.' Hercules operates as an internally managed BDC and does not publish standardized pricing.

htgc.com
2Sample deal: Lexicon Pharmaceuticals — $100M loan facility at prime + 3.1% with 9.85% floor, 18-month interest-only period
ModelUsage-basedBilling cadenceMulti-year contract
Notes

Floating-rate senior secured term loans. Example: Lexicon deal carried a floating interest rate of prime plus 3.1% with a 9.85% floor, 18-month interest-only period, full repayment due May 2030. Terms vary by borrower risk profile.

investing.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Ventured Growth
Description

Hercules Capital's branded podcast featuring interviews with finance leaders and innovators.

htgc.com
Core offering1 text field

Hercules Capital provides non-dilutive senior secured venture debt and equity co-investments to venture-backed and growth-stage technology and life sciences companies. The company originates customized floating-rate loan facilities — typically priced at prime plus a spread with interest-only periods — alongside equity co-investments and milestone-based tranches, supporting use cases from clinical development and runway extension to acquisitions and IPO preparation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • $1.81 billion record new debt and equity commitments in Q1 2026
+5 more records
Product overview1 text field

Hercules Capital operates as a single unified specialty finance platform — the largest business development company (BDC) focused on venture lending — structured around two core service verticals: Hercules Capital Technology Lending and Hercules Capital Life Sciences Lending. Together, these verticals form the company's non-dilutive growth capital offering for innovative, venture-backed entrepreneurs and their VC partners across technology and life sciences sectors. Beyond its core lending business, Hercules Capital also operates the Ventured Growth Podcast as a thought leadership and brand-building platform, featuring CFO and founder conversations that reinforce its position in the innovation economy. Since inception in December 2003, Hercules has committed over $27 billion to more than 700 companies, with a dedicated Technology Group (led by Steve Kuo) and Life Sciences Group (led by R. Bryan Jadot) operating as integrated sub-platforms within the larger BDC.

Product and service1 record
1Hercules Capital Technology Lending
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCore Service ProviderTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-06-18
Description

PricewaterhouseCoopers LLP is Hercules Capital's independent auditor, with ratification of PwC as auditor for 2026 on the agenda of the June 18, 2026 Annual Meeting of Stockholders. Proxy statement was filed on April 23, 2026.

Strategic tierFeatured Portfolio Company / Co-PromotionTypeStrategic or Co-development PartnerAnnounced on2026-05-26
Description

Featured portfolio company; Hercules Capital featured Fin's CFO Dan Griggs on the Ventured Growth podcast discussing Fin's $250 million in debt financing from Hercules and the AI-native customer service transformation. Intercom rebranded to Fin on May 12, 2026.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Largest publicly traded BDC (NASDAQ: ARCC) managed by Ares Management. Operates a much broader middle-market direct lending strategy rather than specializing in venture-backed tech and life sciences, but is the dominant incumbent in the BDC category.

TypeBroad incumbent
Description

Large alternative credit manager with a venture lending unit that competes for direct lending deals. Broader middle-market focus but with venture debt capabilities that overlap with Hercules.

TypeBroad incumbent
Description

Diversified financial services firm with a venture lending group (acquired from PacWest) that competes for tech venture debt deals. Several Hercules MDs (e.g., Ruslan Sergeyev) came from Stifel's venture lending team.

TypeBroad incumbent
Description

Large alternative asset manager with venture lending capabilities including direct lending to growth-stage companies. Competes indirectly through its private credit funds, including co-investment alongside Hercules in deals like Perk.

TypeDirect peer
Description

Publicly traded business development company (NASDAQ: TRIN) providing venture debt and equipment financing to growth-stage technology and life sciences companies. Highly comparable business model, including sponsor finance and life sciences verticals.

TypeDirect peer
Description

Direct venture debt competitor focused on technology and life sciences growth-stage companies with senior secured loans and warrants. Closest comparable in terms of vertical focus, ticket size, and equity co-investment model.

TypeDirect peer
Description

Specialty finance company (Apollo-managed) providing senior secured loans to growth and middle-market companies across healthcare, technology, and life sciences. Competes head-to-head with Hercules in life sciences venture lending.

TypeDirect peer
Description

Publicly traded specialty finance company (NASDAQ: RWAY) providing senior secured loans to venture and non-venture growth-stage companies, with overlap in tech and life sciences verticals.

TypeDirect peer
Description

Specialty finance firm (now part of Axos Financial) that provides senior secured loans to life sciences and healthcare companies. Several Hercules executives, including Adam Soller, came from Oxford, highlighting direct competitive overlap.

TypeDirect peer
Description

BDC (NASDAQ: HRZN) that provides secured loans to development-stage and venture-backed technology, life sciences, healthcare, and sustainability companies. Closely mirrors Hercules' venture lending strategy and loan structure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers19 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment347 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hercules Capital

Venture Lending / Specialty Financehtgc.com

Hercules Capital firmographics

Firmographics
Name
Hercules Capital
Legal name
Hercules Capital, Inc.
Website
https://htgc.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Hercules Capital industry classification

Industry
Product category
Venture Lending / Specialty Finance
NAICS
Funds, Trusts, and Other Financial Vehicles (525), Commercial Banking (522110)
SIC
Short-Term Business Credit Institutions (6153)
akta.pro primary industry
Venture Debt with Warrants (Hybrid Debt-Equity) (FSANAIAI)
akta.pro secondary industries
Independent Venture Debt Funds / Platforms (FSANAIAB), Venture Growth / Recurring Revenue Credit Funds (FSANAIAG)

Keywords

  • Venture debt financing
  • Senior secured loans
  • Business development company
  • Growth capital lending
  • Non-dilutive financing

Where Hercules Capital is headquartered

Location

Headquarters

HQ city
San Mateo
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Hercules Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Others, Technology or R&D

Revenue model

  1. Interest income from senior secured debt investments: Primary revenue stream from interest income on a portfolio of senior secured venture growth loans. Q1 2026 total investment income reached $141.5 million, up 18.4% year-over-year, with $123.4M in total interest income. Portfolio is 98% floating-rate, providing yield upside as base rates rise. Effective portfolio yield was 12.8% in Q1 2026.
  2. Equity investment returns and warrants: Equity co-investments alongside debt positions, generating returns through capital gains, dividends, and warrant exercises. Variable component contributes to the supplemental dividend (e.g., $0.07 supplemental added to base $0.40 dividend in Q1 2026).
  3. Net Investment Income (NII): Record NII of $88.1 million ($0.48 per share) in Q1 2026, representing a 14% year-over-year increase. NII covered the dividend at 120%, demonstrating strong earnings support with $149.1M in spillover income available.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom venture debt financing — quote-based, not publicly disclosed
Usage-basedMulti-year contractSample deal: Lexicon Pharmaceuticals — $100M loan facility at prime + 3.1% with 9.85% floor, 18-month interest-only period

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Hercules Capital product offering

Product offering

Core offering

Hercules Capital provides non-dilutive senior secured venture debt and equity co-investments to venture-backed and growth-stage technology and life sciences companies. The company originates customized floating-rate loan facilities — typically priced at prime plus a spread with interest-only periods — alongside equity co-investments and milestone-based tranches, supporting use cases from clinical development and runway extension to acquisitions and IPO preparation.

Product overview

Hercules Capital operates as a single unified specialty finance platform — the largest business development company (BDC) focused on venture lending — structured around two core service verticals: Hercules Capital Technology Lending and Hercules Capital Life Sciences Lending. Together, these verticals form the company's non-dilutive growth capital offering for innovative, venture-backed entrepreneurs and their VC partners across technology and life sciences sectors. Beyond its core lending business, Hercules Capital also operates the Ventured Growth Podcast as a thought leadership and brand-building platform, featuring CFO and founder conversations that reinforce its position in the innovation economy. Since inception in December 2003, Hercules has committed over $27 billion to more than 700 companies, with a dedicated Technology Group (led by Steve Kuo) and Life Sciences Group (led by R. Bryan Jadot) operating as integrated sub-platforms within the larger BDC.

Differentiator

Problem solved

Functional benefit

Brands

  • Ventured Growth: Hercules Capital's branded podcast featuring interviews with finance leaders and innovators.

Products and services

  • Hercules Capital Technology Lending

Quantifiable outcome

  • $1.81 billion record new debt and equity commitments in Q1 2026
  • +5 more outcomes

Companies that use Hercules Capital

Customer profile

Named customers19 records

Segments5 records

Ideal customer profiles3 records

Hercules Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Hercules Capital partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core service provider and featured portfolio company / co-promotion.

  • PricewaterhouseCoopers LLPcore service providerImplementation/ SI/ Consulting Partner · 18 June 2026PricewaterhouseCoopers LLP is Hercules Capital's independent auditor, with ratification of PwC as auditor for 2026 on the agenda of the June 18, 2026 Annual Meeting of Stockholders. Proxy statement was filed on April 23, 2026.
  • Fin (Intercom)featured portfolio company / co-promotionStrategic or Co-development Partner · 26 May 2026Featured portfolio company; Hercules Capital featured Fin's CFO Dan Griggs on the Ventured Growth podcast discussing Fin's $250 million in debt financing from Hercules and the AI-native customer service transformation. Intercom rebranded to Fin on May 12, 2026.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Hercules Capital competitors and assessment

Company assessment

Broad incumbents

  • Ares Capital: Largest publicly traded BDC (NASDAQ: ARCC) managed by Ares Management. Operates a much broader middle-market direct lending strategy rather than specializing in venture-backed tech and life sciences, but is the dominant incumbent in the BDC category.
  • Golub Capital: Large alternative credit manager with a venture lending unit that competes for direct lending deals. Broader middle-market focus but with venture debt capabilities that overlap with Hercules.
  • Stifel Financial: Diversified financial services firm with a venture lending group (acquired from PacWest) that competes for tech venture debt deals. Several Hercules MDs (e.g., Ruslan Sergeyev) came from Stifel's venture lending team.
  • Blue Owl Capital: Large alternative asset manager with venture lending capabilities including direct lending to growth-stage companies. Competes indirectly through its private credit funds, including co-investment alongside Hercules in deals like Perk.

Direct peers

  • Trinity Capital: Publicly traded business development company (NASDAQ: TRIN) providing venture debt and equipment financing to growth-stage technology and life sciences companies. Highly comparable business model, including sponsor finance and life sciences verticals.
  • TriplePoint Capital: Direct venture debt competitor focused on technology and life sciences growth-stage companies with senior secured loans and warrants. Closest comparable in terms of vertical focus, ticket size, and equity co-investment model.
  • MidCap Financial: Specialty finance company (Apollo-managed) providing senior secured loans to growth and middle-market companies across healthcare, technology, and life sciences. Competes head-to-head with Hercules in life sciences venture lending.
  • Runway Growth Finance: Publicly traded specialty finance company (NASDAQ: RWAY) providing senior secured loans to venture and non-venture growth-stage companies, with overlap in tech and life sciences verticals.
  • Oxford Finance: Specialty finance firm (now part of Axos Financial) that provides senior secured loans to life sciences and healthcare companies. Several Hercules executives, including Adam Soller, came from Oxford, highlighting direct competitive overlap.
  • Horizon Technology Finance: BDC (NASDAQ: HRZN) that provides secured loans to development-stage and venture-backed technology, life sciences, healthcare, and sustainability companies. Closely mirrors Hercules' venture lending strategy and loan structure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Hercules Capital social profiles

Digital presence

Hercules Capital compliance and trust

Trust signal

Compliance2 records

Hercules Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hercules Capital leadership team

Management profile

Number of profiles

Profiles11 records

Hercules Capital subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Hercules Capital funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hercules Capital M&A and investment

M&A and investment

M&A1 record

Investments347 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hercules Capital

What does Hercules Capital do?

Hercules Capital provides non-dilutive senior secured venture debt and equity co-investments to venture-backed and growth-stage technology and life sciences companies. The company originates customized floating-rate loan facilities — typically priced at prime plus a spread with interest-only periods — alongside equity co-investments and milestone-based tranches, supporting use cases from clinical development and runway extension to acquisitions and IPO preparation.

Is Hercules Capital a public or private company?

Hercules Capital is a public company. It is classified as public and is currently operating.

When was Hercules Capital founded?

Hercules Capital was founded in 2003. It employs 101 to 250 people.

Where is Hercules Capital based?

Hercules Capital is headquartered in San Mateo, United States, in the North America region.

How does Hercules Capital make money?

Three revenue lines are on record. Interest income from senior secured debt investments are the primary driver. The others are equity investment returns and warrants and net Investment Income (NII).

Who are Hercules Capital's main competitors?

Broad incumbents on record are Ares Capital, Golub Capital, Stifel Financial and Blue Owl Capital. Direct peers are Trinity Capital, TriplePoint Capital, MidCap Financial, Runway Growth Finance, Oxford Finance and Horizon Technology Finance.

Does Hercules Capital have an API?

No public API is recorded for Hercules Capital.

What industry is Hercules Capital in?

Hercules Capital's product category is Venture Lending / Specialty Finance. Its primary akta.pro industry code is FSANAIAI, Venture Debt with Warrants (Hybrid Debt-Equity), with a secondary code of FSANAIAB, Independent Venture Debt Funds / Platforms. Its NAICS code is 525 and its SIC code is 6153.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ticker ReportHead to Head Review: Blue Owl Capital (NYSE:OBDC) and Hercules Capital (NYSE:HTGC)Hercules Capital and Blue Owl Capital are compared on profitability, risk, institutional ownership, dividends, and analyst ratings. Blue Owl Capital shows higher revenue, earnings, and dividend yield, with a 27% upside target versus Hercules' 14.4%. Analysts favor Blue Owl Capital despite Hercules' lower valuation.Ticker ReportLPL Financial (NASDAQ:LPLA) vs. Hercules Capital (NYSE:HTGC) Head to Head AnalysisLPL Financial beats Hercules Capital on 10 of 18 factors, including higher revenue and earnings. LPL's consensus price target implies a 24.42% upside versus 14.40% for Hercules. LPL also has lower valuation multiples and higher institutional ownership.MarketBeatSound Income Strategies LLC Purchases 110,177 Shares of Hercules Capital, Inc. $HTGCSound Income Strategies LLC increased its Hercules Capital stake by 3.0% in Q3, buying 110,177 shares to own 2.02% of the company. Hercules Capital reported Q2 EPS of $0.50, beating estimates, and declared a $0.40 quarterly dividend. Analysts rate the stock a Moderate Buy with a consensus target of $18.89.AInvestHercules Capital (HTGC) Advances While Market Declines: Some Information for InvestorsHercules Capital shares rose 1.16% to $16.55, outpacing the S&P 500's decline. Analysts expect EPS of $0.49 and revenue of $142.2 million, with a Zacks Rank of #3 (Hold) and a forward P/E of 8.39.American Banking and Market NewsMoelis & Company (NYSE:MC) vs. Hercules Capital (NYSE:HTGC) Financial ContrastMoelis & Company and Hercules Capital are compared across dividends, risk, analyst ratings, and valuation. Hercules Capital has a higher dividend yield (9.8% vs 4.6%) and lower beta (0.82 vs 1.91), while Moelis & Company shows higher revenue and a larger potential upside (30.85% vs 15.24%). Moelis & Company beats Hercules Capital on 9 of 17 factors.Pharmaceutical TechnologyRocket receives $150m credit facility to advance cardiovascular portfolioRocket Pharmaceuticals entered a $150m credit facility with Hercules Capital to fund its cardiovascular portfolio. The company will use proceeds for its Phase II trial of RP-A501 for Danon disease, drawing an initial $35m. The facility includes staged tranches and warrants, with further funding potentially extending into 2029.The Pharma LetterRocket Pharma secures up to $150M credit facilityRocket Pharmaceuticals entered a credit facility agreement with Hercules Capital for up to $150 million. The facility supports its Phase II study of RP-A501 for Danon disease and its cardiovascular pipeline. Shares closed down 5% at $2.48.FinancialContent Business Page1 Stock Under $50 with Competitive Advantages and 2 We Turn DownStockStory evaluates three stocks under $50, recommending Kinder Morgan for its strong margins and cash flow, while advising against Grocery Outlet and Hercules Capital due to weak sales trends and high debt. Kinder Morgan trades at 21x forward P/E, while Grocery Outlet and Hercules Capital carry elevated debt ratios.Pulse 2.0NorthStar Secures Up To $185 Million Growth Financing From Hercules CapitalNorthStar Medical Technologies secured up to $185 million in growth financing from Hercules Capital, with $100 million available upfront. The funds will expand production of no-carrier-added Actinium-225 and its radiopharmaceutical manufacturing. NorthStar plans to transition to a higher-capacity production line later in 2026.American Banking and Market NewsHercules Capital (NYSE:HTGC) versus LPL Financial (NASDAQ:LPLA) Head-To-Head AnalysisLPL Financial beats Hercules Capital on 10 of 18 factors, including higher revenue and earnings, but Hercules offers a higher dividend yield. LPL has a consensus price target of $403.79 (27.6% upside) versus Hercules' $18.89 (12.8% upside). Analysts favor LPL, while Hercules is the better dividend stock.